Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.

[1]  Austin G Smith,et al.  The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity , 2012, Neurobiology of Disease.

[2]  C. Ross,et al.  Age, CAG repeat length, and clinical progression in Huntington's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[4]  J. Mertens,et al.  Excitation-induced ataxin-3 aggregation in neurons from patients with Machado–Joseph disease , 2011, Nature.

[5]  M. Hayden,et al.  Cholesterol metabolism in Huntington disease , 2011, Nature Reviews Neurology.

[6]  M. MacDonald,et al.  HD CAG-correlated gene expression changes support a simple dominant gain of function. , 2011, Human molecular genetics.

[7]  R. Fernández‐Bolaños,et al.  Important role of oxidative stress biomarkers in Huntington's disease. , 2011, Journal of medicinal chemistry.

[8]  D. Krainc,et al.  Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells , 2011, The Journal of Neuroscience.

[9]  C. Svendsen,et al.  Induced pluripotent stem cells: a new revolution for clinical neurology? , 2011, The Lancet Neurology.

[10]  S. Haggarty,et al.  Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. , 2011, Human molecular genetics.

[11]  Blake Byers,et al.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. , 2011, Cell stem cell.

[12]  T. Timmusk,et al.  Identification of cis-Elements and Transcription Factors Regulating Neuronal Activity-Dependent Transcription of Human BDNF Gene , 2011, The Journal of Neuroscience.

[13]  U. Schmidt,et al.  Derivation of Huntington's disease-affected human embryonic stem cell lines. , 2011, Stem cells and development.

[14]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[15]  Daniel T. Montoro,et al.  Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells , 2010, PLoS currents.

[16]  Cameron Torcassi,et al.  Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington's Disease , 2010, Neuron.

[17]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[18]  M. Guillermier,et al.  In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects , 2010, Human molecular genetics.

[19]  J. Alberch,et al.  Impaired TrkB-mediated ERK1/2 Activation in Huntington Disease Knock-in Striatal Cells Involves Reduced p52/p46 Shc Expression* , 2010, The Journal of Biological Chemistry.

[20]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[21]  M. Mehler,et al.  Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease , 2009, Proceedings of the National Academy of Sciences.

[22]  J. Jia,et al.  Polymorphism of HD and UCHL-1 genes in Huntington’s disease , 2009, Journal of Clinical Neuroscience.

[23]  E. Cattaneo,et al.  Brain-derived neurotrophic factor in neurodegenerative diseases , 2009, Nature Reviews Neurology.

[24]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[25]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[26]  M. Peschanski,et al.  Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats , 2008, Proceedings of the National Academy of Sciences.

[27]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[28]  J. Marsh,et al.  CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice , 2008, Molecular and Cellular Neuroscience.

[29]  B. Thiers.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[30]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[31]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[32]  R. Bontrop,et al.  Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas , 2007, BMC Genetics.

[33]  Wenya Linda Bi,et al.  Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. , 2007, Human molecular genetics.

[34]  L. Raymond,et al.  N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.

[35]  C. Ross,et al.  Transcription meets metabolism in neurodegeneration , 2006, Nature Medicine.

[36]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[37]  M. MacDonald,et al.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.

[38]  S. Snyder,et al.  p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease , 2005, Neuron.

[39]  Steven Finkbeiner,et al.  Automated microscope system for determining factors that predict neuronal fate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Hervé Chneiweiss,et al.  Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. , 2005, Human molecular genetics.

[41]  K. Takata,et al.  High mobility group box protein‐1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity , 2004 .

[42]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[43]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[44]  J. Poirier,et al.  A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain , 2004, Neurobiology of Disease.

[45]  K. Takata,et al.  High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. , 2004, Journal of neuroscience research.

[46]  K. Lindenberg,et al.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.

[47]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[48]  Clive N Svendsen,et al.  A new method for the rapid and long term growth of human neural precursor cells , 1998, Journal of Neuroscience Methods.

[49]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[50]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[51]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.